660 related articles for article (PubMed ID: 32366291)
1. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
[TBL] [Abstract][Full Text] [Related]
3. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
4. A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT.
Jouneau S; Gamez AS; Traclet J; Nunes H; Marchand-Adam S; Kessler R; Israël-Biet D; Borie R; Strombom I; Scalori A; Crestani B; Valeyre D; Cottin V
Respiration; 2019; 98(1):19-28. PubMed ID: 30965332
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
7. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
[TBL] [Abstract][Full Text] [Related]
8. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
[TBL] [Abstract][Full Text] [Related]
9. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M
Respiration; 2014; 88(3):199-207. PubMed ID: 25115833
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
12. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis.
Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T
Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting.
Coşkun F; Çilli A; Hanta İ; Sevinç C; Ödemiş A; Ursavaş A
Turk J Med Sci; 2021 Dec; 51(6):3082-3088. PubMed ID: 34565135
[TBL] [Abstract][Full Text] [Related]
15. A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study.
Majewski S; Białas AJ; Barczyk A; Batura-Gabryel H; Buchczyk M; Doboszyńska A; Górska K; Grabowska-Skudlarz L; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krawczyk M; Krenke R; Lewandowska K; Mackiewicz B; Martusewicz-Boros MM; Milanowski J; Noceń-Piskorowska M; Nowicka A; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Stachura T; Tomczak M; Tomkowski W; Trzaska-Sobczak M; Ziora D; Żołnowska B; Piotrowski WJ
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510750
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S
Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787
[TBL] [Abstract][Full Text] [Related]
18. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.
Vancheri C; Sebastiani A; Tomassetti S; Pesci A; Rogliani P; Tavanti L; Luppi F; Harari S; Rottoli P; Ghirardini A; Kirchgaessler KU; Albera C
Respir Med; 2019 Sep; 156():78-84. PubMed ID: 31445389
[TBL] [Abstract][Full Text] [Related]
19. Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.
Wijsenbeek MS; Grutters JC; Wuyts WA
Adv Ther; 2015 Jul; 32(7):691-704. PubMed ID: 26173796
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
